<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: In patients with <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> and reduced ejection fraction, <z:chebi fb="0" ids="2663">amiodarone</z:chebi> reduces mortality by decreasing <z:hpo ids='HP_0001699'>sudden death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Because the latter may be triggered by coronary artery <z:mp ids='MP_0005048'>thrombosis</z:mp> as much as <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, <z:chebi fb="0" ids="2663">amiodarone</z:chebi> might interfere with tissue factor (TF) expression and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Clinically relevant plasma concentrations of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> reduced TF activity and impaired carotid artery <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in a mouse photochemical injury model in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>PTT, aPTT, and tail <z:mp ids='MP_0001914'>bleeding</z:mp> time were not affected; platelet number was slightly decreased </plain></SENT>
<SENT sid="4" pm="."><plain>In human endothelial and vascular smooth muscle cells, <z:chebi fb="0" ids="2663">amiodarone</z:chebi> inhibited <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF)-alpha and thrombin-induced TF expression as well as surface activity </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> lacking <z:chebi fb="60" ids="24859">iodine</z:chebi> and the main metabolite of <z:chebi fb="0" ids="2663">amiodarone</z:chebi>, N-monodesethylamiodarone, inhibited TF expression </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> did not affect <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase activation, TF <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression, and TF protein degradation </plain></SENT>
<SENT sid="7" pm="."><plain>Metabolic labeling confirmed that <z:chebi fb="0" ids="2663">amiodarone</z:chebi> inhibited TF protein translation </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="2663">Amiodarone</z:chebi> impairs <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in vivo; in line with this, it inhibits TF protein expression and surface activity in human vascular cells </plain></SENT>
<SENT sid="9" pm="."><plain>These pleiotropic actions occur within the range of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> concentrations measured in patients, and thus may account at least in part for its beneficial effects in patients with <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> </plain></SENT>
</text></document>